Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Floor Backes

Showing results (21-30 of 56) with videos related to

Pageof 6
Sort By:
Cancer|December 21, 2023
NRG-GY012: Randomized phase 2 study comparing olaparib, cediranib, and the combination of cediranib/olaparib in women with recurrent, persistent, or metastatic endometrial cancerBobbie J Rimel, Danielle Enserro, David P Bender, et al.
Gynecologic Oncology|April 3, 2026
Evaluation of immunotherapy response in the radiated field in patients with recurrent endometrial and cervical cancerJulia Chalif, Molly Morton, Anna Gonzalez, et al.
Gynecologic Oncology Reports|July 20, 2022
High pre-treatment neutrophil-to-lymphocyte ratio as a prognostic marker for worse survival in patients with recurrent/metastatic cervical cancer treated with immune checkpoint inhibitorsCorinne A Calo, David A Barrington, Morgan Brown, et al.
Gynecologic Oncology|January 18, 2017
A phase 2 study of alisertib (MLN8237) in recurrent or persistent uterine leiomyosarcoma: An NRG Oncology/Gynecologic Oncology Group study 0231DDavid M Hyman, Michael W Sill, Heather A Lankes, et al.
Oncogene|April 10, 2025
Circulating extracellular vesicles protein expression for early prediction of platinum-resistance in high-grade serous ovarian cancerVincent Wagner, Molly Morton, Kalpana Deepa Priya Dorayappan, et al.
NPJ Precision Oncology|July 10, 2023
ALDH1A1 promotes PARP inhibitor resistance by enhancing retinoic acid receptor-mediated DNA polymerase θ expressionKousalya Lavudi, Ananya Banerjee, Na Li, et al.
Gynecologic Oncology|December 5, 2023
Lunchbox trial: A randomized phase III trial of cisplatin and irradiation followed by carboplatin and paclitaxel versus sandwich therapy of carboplatin and paclitaxel followed by irradiation then carboplatin and paclitaxel for advanced endometrial carcinomaJoyce N Barlin, Barb Mahar, Ashar Ata, et al.
Cells|April 27, 2026
Serum Extracellular Vesicle Protein Signatures Associated with Early-Stage High-Grade Serous Ovarian CarcinomaMichelle Lightfoot, Kalpana Deepa Priya Dorayappan, Vignesh Vudatha, et al.
Gynecologic Oncology Reports|September 2, 2025
Exploratory evaluation of immunotherapy response and medication use in endometrial and cervical carcinomaJulia Chalif, Molly Morton, Eric McLaughlin, et al.
Gynecologic Oncology|June 27, 2026
PRO-PLATINUM: A randomized, double-blind, placebo controlled study to investigate the efficacy of a probiotic intervention on the gut and vaginal microbiome of ovarian cancer patients undergoing treatment with platinum chemotherapyLaura M Chambers, Daniel Spakowicz, Julia Chalif, et al.
Pageof 6

Showing results (21-30 of 56) with videos related to

Sort By:
Pageof 6
Cancer|December 21, 2023
NRG-GY012: Randomized phase 2 study comparing olaparib, cediranib, and the combination of cediranib/olaparib in women with recurrent, persistent, or metastatic endometrial cancerBobbie J Rimel, Danielle Enserro, David P Bender, et al.
Gynecologic Oncology|April 3, 2026
Evaluation of immunotherapy response in the radiated field in patients with recurrent endometrial and cervical cancerJulia Chalif, Molly Morton, Anna Gonzalez, et al.
Gynecologic Oncology Reports|July 20, 2022
High pre-treatment neutrophil-to-lymphocyte ratio as a prognostic marker for worse survival in patients with recurrent/metastatic cervical cancer treated with immune checkpoint inhibitorsCorinne A Calo, David A Barrington, Morgan Brown, et al.
Gynecologic Oncology|January 18, 2017
A phase 2 study of alisertib (MLN8237) in recurrent or persistent uterine leiomyosarcoma: An NRG Oncology/Gynecologic Oncology Group study 0231DDavid M Hyman, Michael W Sill, Heather A Lankes, et al.
Oncogene|April 10, 2025
Circulating extracellular vesicles protein expression for early prediction of platinum-resistance in high-grade serous ovarian cancerVincent Wagner, Molly Morton, Kalpana Deepa Priya Dorayappan, et al.
NPJ Precision Oncology|July 10, 2023
ALDH1A1 promotes PARP inhibitor resistance by enhancing retinoic acid receptor-mediated DNA polymerase θ expressionKousalya Lavudi, Ananya Banerjee, Na Li, et al.
Gynecologic Oncology|December 5, 2023
Lunchbox trial: A randomized phase III trial of cisplatin and irradiation followed by carboplatin and paclitaxel versus sandwich therapy of carboplatin and paclitaxel followed by irradiation then carboplatin and paclitaxel for advanced endometrial carcinomaJoyce N Barlin, Barb Mahar, Ashar Ata, et al.
Cells|April 27, 2026
Serum Extracellular Vesicle Protein Signatures Associated with Early-Stage High-Grade Serous Ovarian CarcinomaMichelle Lightfoot, Kalpana Deepa Priya Dorayappan, Vignesh Vudatha, et al.
Gynecologic Oncology Reports|September 2, 2025
Exploratory evaluation of immunotherapy response and medication use in endometrial and cervical carcinomaJulia Chalif, Molly Morton, Eric McLaughlin, et al.
Gynecologic Oncology|June 27, 2026
PRO-PLATINUM: A randomized, double-blind, placebo controlled study to investigate the efficacy of a probiotic intervention on the gut and vaginal microbiome of ovarian cancer patients undergoing treatment with platinum chemotherapyLaura M Chambers, Daniel Spakowicz, Julia Chalif, et al.
Pageof 6